CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Open-label Study of Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04281498
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:53.988105+00:00
Published At: 2024-12-18T00:00:00+00:00
Record Updated At: 2025-02-04
Results Posted At: 2024-12-18
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Accelerated/Blast-phase Myeloproliferative Neoplasm", "Chronic-phase Myelofibrosis", "IDH2 Mutation"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-02-04"
protocolSection.identificationModule.nctId: "NCT04281498"
protocolSection.identificationModule.officialTitle: "A Phase II Open-label Study of Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2024-12-18"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.